Publication Abstract from PubMed
The main protease (M (pro)) of coronaviruses plays a key role in viral replication, thus serving as a hot target for drug design. PF-00835231 is a promising inhibitor of SARS-CoV-2 M (pro). Here, we report the inhibitory potency of PF-00835231 against SARS-CoV-2 M (pro) and seven M (pro) mutants (G15S, M49I, Y54C, K90R, P132H, S46F, and V186F) from SARS-CoV-2 variants. The results confirm that PF-00835231 has broad-spectrum inhibition against various coronaviral M (pro)s. In addition, the crystal structures of SARS-CoV-2 M (pro), SARS-CoV M (pro), MERS-CoV M (pro), and seven SARS-CoV-2 M (pro) mutants (G15S, M49I, Y54C, K90R, P132H, S46F, and V186F) in complex with PF-00835231 are solved. A detailed analysis of these structures reveals key determinants essential for inhibition and elucidates the binding modes of different coronaviral M (pro)s. Given the importance of the main protease for the treatment of coronaviral infection, structural insights into M (pro) inhibition by PF-00835231 can accelerate the design of novel antivirals with broad-spectrum efficacy against different human coronaviruses.
Structural basis for the inhibition of coronaviral main proteases by PF-00835231.,Zhou X, Lu X, Lin C, Zou X, Li W, Zeng X, Wang J, Zeng P, Wang W, Zhang J, Jiang H, Li J Acta Biochim Biophys Sin (Shanghai). 2024 Jul 29;56(12):1813-1822. doi: , 10.3724/abbs.2024122. PMID:39076076[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
